ERBB2 and gastric cancer: After negative outcomes from successive phase III trials investigating the efficacy of alternative first- or second-line treatments in HER2-positive gastric cancers, more recent data has indicated efficacy with immunotherapy-based approaches and ADCs, and further insight into the biology of primary and acquired resistance to HER2-targeted agents has deepened our understanding into mechanisms of primary and acquired resistance.